These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20443737)

  • 1. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
    Burbelo PD; Issa AT; Ching KH; Wyvill KM; Little RF; Iadarola MJ; Kovacs JA; Yarchoan R
    J Infect Dis; 2010 Jun; 201(12):1919-22. PubMed ID: 20443737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
    Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
    Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
    J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.
    Katano H; Sato Y; Kurata T; Mori S; Sata T
    Virology; 2000 Apr; 269(2):335-44. PubMed ID: 10753712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study.
    Benavente Y; Mbisa G; Labo N; Casabonne D; Becker N; Maynadie M; Foretova L; Cocco PL; Nieters A; Staines A; Bofetta P; Brennan P; Whitby D; de Sanjosé S
    Br J Cancer; 2011 Nov; 105(11):1768-71. PubMed ID: 21952625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.
    Amodio E; Goedert JJ; Barozzi P; Riva G; Firenze A; Bonura F; Viviano E; Romano N; Luppi M
    Cancer Sci; 2011 Oct; 102(10):1769-73. PubMed ID: 21740480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
    Uldrick TS; Wang V; O'Mahony D; Aleman K; Wyvill KM; Marshall V; Steinberg SM; Pittaluga S; Maric I; Whitby D; Tosato G; Little RF; Yarchoan R
    Clin Infect Dis; 2010 Aug; 51(3):350-8. PubMed ID: 20583924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.
    Wen KW; Damania B
    Cancer Lett; 2010 Mar; 289(2):140-50. PubMed ID: 19651473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the frequency of antibody and titers against human herpesvirus 8 latent and lytic antigens in "at-risk" individuals and among patients with Kaposi's sarcoma.
    Magri MC; Carbone PH; de los Santos-Fortuna E; Caterino-de-Araujo A
    J Med Virol; 2009 Jul; 81(7):1292-7. PubMed ID: 19475629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases.
    Lage SL; Ramaswami R; Rocco JM; Rupert A; Davis DA; Lurain K; Manion M; Whitby D; Yarchoan R; Sereti I
    Blood; 2024 Oct; 144(14):1496-1507. PubMed ID: 38941593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency.
    Mariggiò G; Koch S; Zhang G; Weidner-Glunde M; Rückert J; Kati S; Santag S; Schulz TF
    PLoS Pathog; 2017 Apr; 13(4):e1006335. PubMed ID: 28430817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of antibodies against latent and lytic antigens of human herpesvirus 8 in an endemic population and patients with Kaposi's sarcoma in Mozambique.
    Caterino-de-Araujo A; Magri MC; Manuel RC
    J Med Virol; 2010 Sep; 82(9):1576-81. PubMed ID: 20648612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.
    Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R
    Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study.
    Enbom M; Sheldon J; Lennette E; Schulz T; Ablashi DV; Neipel F; Biberfeld P; Carlberg H; Ljungman P; Nilsson A; Söderström T; Wadström J; Linde A
    J Med Virol; 2000 Dec; 62(4):498-504. PubMed ID: 11074479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.
    Sabbah S; Jagne YJ; Zuo J; de Silva T; Ahasan MM; Brander C; Rowland-Jones S; Flanagan KL; Hislop AD
    Blood; 2012 Mar; 119(9):2083-92. PubMed ID: 22234686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system.
    Lopez M; Kainthla R; Lazarte S; Chen W; Nijhawan AE; Knights S
    Eur J Haematol; 2024 May; 112(5):723-730. PubMed ID: 38155405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.
    Sullivan RJ; Pantanowitz L; Casper C; Stebbing J; Dezube BJ
    Clin Infect Dis; 2008 Nov; 47(9):1209-15. PubMed ID: 18808357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.
    Kim B; Jeon YK; Kim CW
    J Korean Med Sci; 2009 Oct; 24(5):970-4. PubMed ID: 19795003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.
    Burbelo PD; Leahy HP; Groot S; Bishop LR; Miley W; Iadarola MJ; Whitby D; Kovacs JA
    Clin Vaccine Immunol; 2009 May; 16(5):621-7. PubMed ID: 19261774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review.
    Dumic I; Radovanovic M; Igandan O; Savic I; Nordstrom CW; Jevtic D; Subramanian A; Ramanan P
    Am J Case Rep; 2020 Dec; 21():e926433. PubMed ID: 33268763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.